JP2025514712A - ブロモドメインに対して活性な化合物 - Google Patents

ブロモドメインに対して活性な化合物 Download PDF

Info

Publication number
JP2025514712A
JP2025514712A JP2024560880A JP2024560880A JP2025514712A JP 2025514712 A JP2025514712 A JP 2025514712A JP 2024560880 A JP2024560880 A JP 2024560880A JP 2024560880 A JP2024560880 A JP 2024560880A JP 2025514712 A JP2025514712 A JP 2025514712A
Authority
JP
Japan
Prior art keywords
methyl
pyridine
dihydrofuro
quinolin
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024560880A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025514712A5 (cg-RX-API-DMAC7.html
Inventor
スミス，ギャリック・ポール
ラスト，スラフコ
スタシ，ルイージ・ピエロ
ペイロ，カダイア・ホルヘ
ポルヤク，ビスニヤ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuevolution AS
Original Assignee
Nuevolution AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuevolution AS filed Critical Nuevolution AS
Publication of JP2025514712A publication Critical patent/JP2025514712A/ja
Publication of JP2025514712A5 publication Critical patent/JP2025514712A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024560880A 2022-04-19 2023-04-19 ブロモドメインに対して活性な化合物 Pending JP2025514712A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE2250473-2 2022-04-19
SE2250473 2022-04-19
PCT/US2023/019121 WO2023205251A1 (en) 2022-04-19 2023-04-19 Compounds active towards bromodomains

Publications (2)

Publication Number Publication Date
JP2025514712A true JP2025514712A (ja) 2025-05-09
JP2025514712A5 JP2025514712A5 (cg-RX-API-DMAC7.html) 2026-04-27

Family

ID=86331094

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024560880A Pending JP2025514712A (ja) 2022-04-19 2023-04-19 ブロモドメインに対して活性な化合物

Country Status (8)

Country Link
US (1) US20250382308A1 (cg-RX-API-DMAC7.html)
EP (1) EP4511119B1 (cg-RX-API-DMAC7.html)
JP (1) JP2025514712A (cg-RX-API-DMAC7.html)
CN (1) CN119365455A (cg-RX-API-DMAC7.html)
AU (1) AU2023255396A1 (cg-RX-API-DMAC7.html)
CA (1) CA3255932A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024013002A (cg-RX-API-DMAC7.html)
WO (1) WO2023205251A1 (cg-RX-API-DMAC7.html)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101910182B (zh) 2007-12-28 2013-07-17 田边三菱制药株式会社 抗癌剂
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
AU2010317096B2 (en) 2009-11-05 2015-03-26 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CA2779355C (en) 2009-11-05 2018-01-16 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
ES2606958T3 (es) 2010-05-14 2017-03-28 Dana-Farber Cancer Institute, Inc. Compuestos de tienotriazolodiazepina para tratar una neoplasia
EP2585465B1 (en) 2010-06-22 2014-11-12 GlaxoSmithKline LLC Benzotriazolodiazepine compounds inhibitors of bromodomains
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
HK1211033A1 (en) 2012-12-20 2016-05-13 Bayer Pharma Aktiengesellschaft Bet-protein-inhibiting dihydroquinoxalinones
JP2016504990A (ja) 2012-12-20 2016-02-18 バイエル ファーマ アクチエンゲゼルシャフト Ｂｅｔタンパク質抑制性ジヒドロピリドピラジノン
SG10201900631TA (en) * 2014-08-01 2019-02-27 Nuevolution As Compounds active towards bromodomains
EP3563851B1 (en) * 2016-12-27 2021-04-21 FUJIFILM Corporation Antitumor agent and bromodomain inhibitor

Also Published As

Publication number Publication date
CN119365455A (zh) 2025-01-24
EP4511119A1 (en) 2025-02-26
WO2023205251A1 (en) 2023-10-26
EP4511119B1 (en) 2026-07-15
US20250382308A1 (en) 2025-12-18
AU2023255396A1 (en) 2024-10-24
CA3255932A1 (en) 2023-10-26
MX2024013002A (es) 2024-11-08

Similar Documents

Publication Publication Date Title
KR20250070059A (ko) 신규한 테트라헤테로사이클 화합물
CN113286794B (zh) Kras突变蛋白抑制剂
JP7335882B2 (ja) ピリミジン縮合環式化合物及びその製造方法、並びに使用
CN113637005A (zh) 用于癌症治疗的kras抑制剂
RU2576384C1 (ru) 3,5-дизамещенное алкинилбензольное соединение и его соль
KR101864561B1 (ko) Jak 억제제
JP5121716B2 (ja) ピリジン誘導体および精神異常の処置におけるそれらの使用
CA3177261A1 (en) Benzothiazolyl biaryl compound, and preparation method and use
US8722661B2 (en) Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
CN115867346B (zh) 激酶抑制剂
CN107530329A (zh) 用作CDK抑制剂的吡唑并[1,5‑a][1,3,5]三嗪和吡唑并[1,5‑a]嘧啶衍生物
AU2018235139A1 (en) Compounds useful in the treatment or prevention of a PRMT5-mediated disorder
HK1223100A1 (zh) 杂环化合物
WO2014078372A1 (en) Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
JP2009507801A5 (cg-RX-API-DMAC7.html)
WO2016007185A1 (en) Aminopyridazinone compounds as protein kinase inhibitors
KR20250092268A (ko) Sting을 활성화시킬 수 있는 헤테로사이클릭 화합물
EP4061817A1 (en) Adenosine receptor antagonist compounds
CN110655520A (zh) 嘧啶并环化合物及其制备方法和应用
CN115916771B (zh) 多靶点的抗肿瘤化合物及其制备方法和应用
CN114075219B (zh) 喹啉稠环类衍生物、其制备方法及其在医药上的应用
TWI894448B (zh) Ctla-4小分子降解劑及其應用
JP6522502B2 (ja) Ｗｎｔシグナル阻害剤
EP4511119A1 (en) Compounds active towards bromodomains
KR20190085112A (ko) Gsk-3 억제제

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260417